BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29137103)

  • 1. Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report.
    Zhu Z; Chai Y
    Medicine (Baltimore); 2017 Nov; 96(45):e8652. PubMed ID: 29137103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
    Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
    J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
    Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.
    Hida T; Satouchi M; Nakagawa K; Seto T; Matsumoto S; Kiura K; Nokihara H; Murakami H; Tokushige K; Hatano B; Nishio M
    Jpn J Clin Oncol; 2017 Jul; 47(7):618-624. PubMed ID: 28369553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
    Kiura K; Imamura F; Kagamu H; Matsumoto S; Hida T; Nakagawa K; Satouchi M; Okamoto I; Takenoyama M; Fujisaka Y; Kurata T; Ito M; Tokushige K; Hatano B; Nishio M
    Jpn J Clin Oncol; 2018 Apr; 48(4):367-375. PubMed ID: 29474558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
    J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
    Gainor JF; Tan DS; De Pas T; Solomon BJ; Ahmad A; Lazzari C; de Marinis F; Spitaleri G; Schultz K; Friboulet L; Yeap BY; Engelman JA; Shaw AT
    Clin Cancer Res; 2015 Jun; 21(12):2745-52. PubMed ID: 25724526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
    J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
    Santarpia M; Daffinà MG; D'Aveni A; Marabello G; Liguori A; Giovannetti E; Karachaliou N; Gonzalez Cao M; Rosell R; Altavilla G
    Drug Des Devel Ther; 2017; 11():2047-2063. PubMed ID: 28740365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
    Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation ALK inhibitors: filling the non "MET" gap.
    Ramalingam SS; Khuri FR
    Cancer Discov; 2014 Jun; 4(6):634-6. PubMed ID: 24891360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.
    Zhu Q; Hu H; Weng DS; Zhang XF; Chen CL; Zhou ZQ; Tang Y; Xia JC
    BMC Cancer; 2017 Jun; 17(1):412. PubMed ID: 28606126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
    Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
    Bendaly E; Dalal AA; Culver K; Galebach P; Bocharova I; Foster R; Sasane M; Macalalad AR; Guérin A
    Adv Ther; 2017 May; 34(5):1145-1156. PubMed ID: 28405961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.